Last reviewed · How we verify
Clindamycin Phosphate Lotion 1%
Clindamycin phosphate inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, reducing acne-causing bacteria and inflammation on the skin.
Clindamycin phosphate inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, reducing acne-causing bacteria and inflammation on the skin. Used for Acne vulgaris (topical treatment), Bacterial skin infections.
At a glance
| Generic name | Clindamycin Phosphate Lotion 1% |
|---|---|
| Sponsor | Balmoral Medical company |
| Drug class | Lincosamide antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Clindamycin is a lincosamide antibiotic that penetrates sebaceous follicles and inhibits bacterial protein synthesis, particularly effective against Propionibacterium acnes. When applied topically as a lotion, it reduces bacterial colonization and associated inflammatory responses in acne lesions. The phosphate salt formulation enhances skin penetration and stability.
Approved indications
- Acne vulgaris (topical treatment)
- Bacterial skin infections
Common side effects
- Dryness or peeling
- Erythema or irritation
- Oiliness or folliculitis
- Contact dermatitis
Key clinical trials
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields (PHASE2)
- Efficacy of Laser Hair Removal Therapy in HS (NA)
- Intradermal LPS and Antibiotics (NA)
- Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris (PHASE3)
- Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients (PHASE4)
- Microwave Ablation in Mild Axillary Hidradenitis Suppurativa (NA)
- Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clindamycin Phosphate Lotion 1% CI brief — competitive landscape report
- Clindamycin Phosphate Lotion 1% updates RSS · CI watch RSS
- Balmoral Medical company portfolio CI